Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

Alpha Synuclein Antibody (Aggregate-Specific), Clone 2F11

Product Sizes
12 ug
SMC-617-12UG
100 ug
SMC-617-100UG
About this Product
SKU:
SMC-617
Additional Names:
Alpha Synuclein, A Alpha-Synuclein, SNCA, Snca, SYN, alphaSYN, NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Parkinson disease familial 1, PARK1, PARK 1, PARK4, PARK 4, Parkinson disease (autosomal dominant, Lewy body) 4, Lewy body 4, Synuclein-alpha, PD1
Application:
Conjugation/Labeling, Dot Blot, Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
Buffer:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
CE/IVD:
RUO
translate.label.attr.clone:
2F11
Clonality:
Monoclonal
Concentration:
1 mg/ml
Extra Details:
Alpha-synuclein (SNCA) is a presynaptic neuronal protein abundantly expressed in the brain, particularly within the olfactory bulb, hippocampus, striatum, and thalamus (1,2). Localized to both synaptic terminals and mitochondria, alpha-synuclein plays a critical role in synaptic vesicle regulation and cytoskeletal dynamics through its interaction with tubulin (3), suggesting a potential function as a microtubule-associated protein. It is also essential for cognitive development, with SNCA inactivation linked to deficits in spatial learning and working memory (4). Pathologically, alpha-synuclein aggregates are a defining feature of several neurodegenerative diseases. These fibrillar inclusions constitute the major non-AB Beta component of amyloid plaques in Alzheimer's disease and are the principal constituents of Lewy bodies in Parkinson's disease (PD). In PD, progressive accumulation of alpha-synuclein and ubiquitin-positive inclusions in dopaminergic neurons is closely associated with motor and cognitive decline (5,6). Alpha-synuclein aggregation is not merely a byproduct of disease but a driver of neurotoxicity, mitochondrial dysfunction, and synaptic failure. Its central role in disease pathogenesis has made it a high-priority target for biomarker development and therapeutic intervention. Covered by US patent family US11,098,108B2 (7).
Host:
Mouse
Immunogen:
Mouse alpha synuclein fibrils
Isotype:
IgG1
Purification:
Protein G Purified
Reactivities:
Human, Mouse
Shipping Conditions:
Blue Ice
Specificity:
This antibody binds a 3-dimensional fibrillar epitope of alpha synuclein (including AA101-120, AA61-80), present in MSA (Multiple System Atrophy) aggregates in human brain samples. It does not appear to detect PD (Parkinson's disease) or PDLB (Parkinson's disease with Lewy Bodies) aggregate structures in human brain samples. It can, however, bind recombinant human PFFs and mouse PFFs.
Storage Conditions:
-20[o]C
Supplier:
StressMarq Biosciences
Type:
Antibody: Monoclonal Antibody
Immuno-gold electron micrograph of sonicated A Alpha-Syn Fibrils (SPR-322) stained with 2F11 antibody (1:400 dilution) and visualized using goat anti-mouse IgG conjugated with 18 nm gold particles. The sample was then placed on a transmission electron microscopy metallic grid and stained with uranyl acetate.
Western blot on 15ug mouse brain lysate from Fmr1 KO mice (FXS mice) with C57Bl/6J genetic background. Block: 5% Skim Milk in 1X TBST. Primary Antibody: Mouse Anti-Alpha Synuclein Monoclonal Antibody clone 2F11 at 1:1000 for 2 hours at RT. Secondary Antibody: Goat Anti-Mouse HRP:IgG at 1:3000 for 1 hour at RT. Color Development: ECL solution (Super Signal West Pico) for 5 min in RT. Band clearly identifies large molecular weight oligomeric band (monomeric band predicted at 14kD).
Western blot on 15ug Hela lysate. Block: 5% Skim Milk in 1X TBST. Primary Antibody: Mouse Anti-Alpha Synuclein Monoclonal Antibody clone 2F11 at 1:1000 for 2 hours at RT. Secondary Antibody: Goat Anti-Mouse HRP:IgG at 1:3000 for 1 hour at RT. Color Development: ECL solution (Super Signal West Pico) for 5 min in RT. Band clearly identifies large molecular weight oligomeric band (monomeric band predicted at 14kD).
SPR binding analysis of 2F11 antibody and human alpha synuclein type 1 fibrils (SPR-322), type 2 (SPR-317) fibrils and monomeric protein (SPR-321). Buffer (top left), alpha synuclein monomers (top right), alpha synuclein fibrils type1 (bottom left), and alpha synuclein fibrils type 2 (bottom right). Data: KD[nM] for SPR-322 = 42.5, SPR-317 = 365.3; 2F11 binds SPR-322 with 8.6 x greater affinity than SPR-317. 2F11 does not bind monomeric alpha synuclein (SPR-321).
8 Day differentiated iPSCs with added alpha synuclein fibrils (SPR-322), conjugated to Alexa Fluor 555 with or without 1h prior 2F11 addition. SPR-322 Alexa Fluor 555 added at 5ug/well for 48h, 2F11 (50ug/well added 1h before fibrils where applicable). Cells were subsequently washed 48h after addition and imaged a following 24h later. Imaging and channels: 2F11 antibody: 647nm (using an anti-mouse-647 conjugate); Fibrils: 555nm, phosph-ser129 (SPR-600) 488nm, and Hoechst stain for DNA. Image 4a top, no fibrils, no 2F11 added. Bottom, fibrils added, no 2F11 antibody. Fibrils are clearly visible in the cells as is enhanced phosph-ser129 signal. Image 4b top, no fibrils, 2F11 antibody added. Bottom, fibrils and 2F11 antibody added. The image clearly shows 2F11 antibody addition stops cell entry of the 555-labelled fibrils.